"Topotecan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
| Descriptor ID |
D019772
|
| MeSH Number(s) |
D03.132.151.850
|
| Concept/Terms |
Topotecan- Topotecan
- 9-Dimethylaminomethyl-10-hydroxycamptothecin
- 9 Dimethylaminomethyl 10 hydroxycamptothecin
Topotecan Hydrochloride- Topotecan Hydrochloride
- Hydrochloride, Topotecan
- Nogitecan Hydrochloride
- Hydrochloride, Nogitecan
- Topotecan Monohydrochloride, (S)-Isomer
SK&F-104864-A- SK&F-104864-A
- SK&F 104864 A
- SK&F104864A
- SKF-104864-A
- SKF 104864 A
- SKF104864A
|
Below are MeSH descriptors whose meaning is more general than "Topotecan".
Below are MeSH descriptors whose meaning is more specific than "Topotecan".
This graph shows the total number of publications written about "Topotecan" by people in this website by year, and whether "Topotecan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 1 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topotecan" by people in Profiles.
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
-
Incidence and Risk Factors for Neutropenia After Intra-Arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol. 2023 12 01; 141(12):1133-1138.
-
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2024 Apr; 262(4):1321-1328.
-
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150.
-
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study. Am J Obstet Gynecol. 2023 04; 228(4):445.e1-445.e8.
-
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365.
-
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 01; 38(1):350-365.
-
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol. 2020 12; 86(6):829-840.
-
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774.
-
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 11 10; 38(32):3753-3762.